- Folding to function
- Rising insights in nonsevere hemophilia A and DDAVP treatment
- Award date
- 9 October 2018
- Number of pages
- Document type
- PhD thesis
- Faculty of Medicine (AMC-UvA)
Hemophilia A (HA) is a bleeding disorder caused by a defect in the F8 gene, leading to decreased clotting factor VIII (FVIII) levels. Patients are classified based on residual FVIII concentration (FVIII:C) in the plasma. Severely affected patients have no detectable FVIII:C levels, whereas nonsevere patients have some activity.
The focus of this thesis is nonsevere HA. The mainstay of nonsevere HA treatment is the replacement of defective FVIII. Replacement therapy by using FVIII concentrates has three downsides. Unfortunately, there is a lifelong risk of the development of inhibiting antibodies against FVIII (inhibitors). When this occurs, the treatment of future bleeding episodes is jeopardized. Furthermore, the frequent intravenous administration of FVIII concentrate due to its short half-life is inconvenient for patients. Lastly, the costs of treatment are a major burden on national healthcare budgets. Resources are limited to treat patients in developing countries. For these reasons, the avoidance of FVIII concentrates by using safer, convenient and cheaper treatment options is preferable.
A safer and relatively cheaper treatment option is desmopressin (DDAVP). DDAVP is a synthetic hormone that increases endogenous FVIII in most, but not all nonsevere HA patients. Deciphering the biomolecular processes underlying the therapeutic effect of DDAVP may help to optimize treatment strategies. Despite rapid developments in the treatment or possible future cure of nonsevere HA, a permanent solution to restore hemostasis in these patients is not yet available. With this thesis I aimed to gain rising insights into nonsevere HA and DDAVP treatment.
Thesis (complete) (Embargo up to and including 9 October 2020)
Chapter 6: The effect of F8 missense mutations on DDAVP response in nonsevere hemophilia A: A new classification method (Embargo up to and including 9 October 2020)
Chapter 7: Age partially explains intra-individual variation in DDAVP response in nonsevere hemophilia A patients (Embargo up to and including 9 October 2020)
Chapter 8: Identification and explanation of inter-patient variability in DDAVP response in nonsevere hemophilia A patients: to identify tools to optimize its use (Embargo up to and including 9 October 2020)
Chapter 10: Population pharmacokinetic modelling: A useful tool to predict response to DDAVP in nonsevere Hemophilia A (Embargo up to and including 9 October 2020)
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library, or send a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.